MedPath

Iterum Therapeutics Achieves FDA Approval for Orlynvah in Treating UTIs

Iterum Therapeutics has reached a significant milestone with the FDA approval of Orlynvah, a treatment for uncomplicated urinary tract infections in adult women, marking its first approved indication and introducing the first oral penem in the U.S.

Iterum Therapeutics has recently achieved a significant milestone with the FDA approval of Orlynvah, a groundbreaking treatment for uncomplicated urinary tract infections (UTIs) in adult women. This approval marks the first indication for Orlynvah and introduces the first oral penem in the United States, setting a new standard in the treatment of UTIs.
This development not only highlights Iterum Therapeutics' commitment to addressing unmet medical needs but also paves the way for new strategic partnerships. The approval of Orlynvah is a testament to the company's innovative approach to developing treatments that offer new hope to patients suffering from UTIs, providing a much-needed alternative to existing therapies.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

FDA Approves Iterum's Oral Sulopenem (ORLYNVAH™) for Uncomplicated Urinary Tract Infections

The FDA has approved ORLYNVAH™ (oral sulopenem) by Iterum Therapeutics for treating uncomplicated urinary tract infections (uUTIs) in adult women.
ORLYNVAH™ is the first oral penem antibiotic approved in the U.S., offering a new treatment option for uUTIs caused by specific microorganisms.

Iterum's Orlynvah Receives FDA Approval for Uncomplicated Urinary Tract Infections

The FDA has approved Orlynvah (sulopenem etzadroxil and probenecid) for uncomplicated urinary tract infections (uUTIs) in adult women with limited oral antibacterial options.
Approval was based on Phase 3 trials SURE 1 and REASSURE, demonstrating superiority to ciprofloxacin and non-inferiority/superiority to Augmentin, respectively.

FDA Approves Iterum's Orlynvah for Uncomplicated Urinary Tract Infections

The FDA has approved Iterum Therapeutics' Orlynvah (sulopenem etzadroxil and probenecid) for treating adult women with uncomplicated urinary tract infections (uUTIs).
Orlynvah, an oral penem antibiotic, targets infections caused by bacteria like Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis, offering an alternative for those with limited options.

Iterum's Oral Antibiotic Orlynvah Approved by FDA for Uncomplicated UTIs

Iterum Therapeutics' Orlynvah (sulopenem etzadroxil and probenecid) has received FDA approval for treating uncomplicated urinary tract infections (uUTIs) in adult women.
Orlynvah is the first oral penem antibiotic approved in the U.S., targeting key uUTI-causing microorganisms like _Escherichia coli_, _Klebsiella pneumoniae_, and _Proteus mirabilis_.

FDA Approves Iterum's Oral Sulopenem (ORLYNVAH™) for Uncomplicated Urinary Tract Infections

The FDA has approved ORLYNVAH™ (oral sulopenem) for treating uncomplicated urinary tract infections (uUTIs) in adult women with limited oral antibacterial options.
ORLYNVAH™ is the first oral penem antibiotic approved in the U.S., offering a new treatment alternative for uUTIs caused by specific microorganisms.

FDA Approves Iterum Therapeutics' Orlynvah for Complicated Urinary Tract Infections

The FDA has approved Iterum Therapeutics' Orlynvah for treating uncomplicated urinary tract infections (uUTIs) in adult women with limited oral antibacterial options.
Orlynvah is the first FDA-approved product for Iterum and the first oral penem antibiotic approved in the U.S., offering a novel treatment option.

FDA Approves Iterum Therapeutics' Orlynvah for Uncomplicated Urinary Tract Infections

The FDA has approved Orlynvah (sulopenem etzadroxil and probenecid) for treating uncomplicated urinary tract infections (uUTIs) in adult women with limited oral antibacterial options.
Orlynvah is the first FDA-approved product for Iterum Therapeutics and the first oral penem antibiotic approved in the U.S. for uUTIs.

FDA Approves Iterum Therapeutics' Orlynvah for Uncomplicated Urinary Tract Infections

The FDA has approved Orlynvah (sulopenem etzadroxil and probenecid) for treating uncomplicated urinary tract infections (uUTIs) in adult women with limited oral antibacterial options.
Orlynvah is the first approved indication for Iterum Therapeutics and the first oral penem antibiotic approved in the U.S., offering a novel treatment option.

FDA Approves Iterum's Oral Sulopenem (ORLYNVAH™) for Uncomplicated Urinary Tract Infections

The FDA has approved ORLYNVAH™ (sulopenem etzadroxil and probenecid) for treating uncomplicated urinary tract infections (uUTIs) in adult women with limited oral antibacterial options.
ORLYNVAH™ is the first oral penem antibiotic approved in the U.S., offering a new treatment alternative for uUTIs caused by specific microorganisms.

FDA Approves Iterum's Oral Penem ORLYNVAH™ for Uncomplicated Urinary Tract Infections

The FDA has approved ORLYNVAH™ (sulopenem etzadroxil and probenecid) for uncomplicated urinary tract infections (uUTIs) in adult women with limited oral treatment options.
ORLYNVAH™ is the first oral penem antibiotic approved in the U.S., offering a new treatment alternative for infections caused by specific resistant microorganisms.

Reference News

[1]
Iterum Therapeutics (NASDAQ:ITRM) Stock Quotes, Forecast and News Summary
benzinga.com · Jan 7, 2025

Iterum Therapeutics' Orlynvah gains FDA approval for treating uncomplicated UTIs in adult women, marking a milestone as ...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy